Called Air by Propeller, it provides local asthma conditions to anyone in the US who would like to share this insight with their audiences.
The two companies will undertake commercial activities using the Propeller clip-on sensor and software platform for use with GSK's ELLIPTA Inhaler.
The new custom sensors will allow for passively recording compliance data, better informing patients and their physicians of adherence and other factors.
The initial focus of the collaboration will be the development of an add-on sensor for Vectura's lever-operated multi-dose inhaler (LOMI).
The study demonstrated effectiveness of the Propeller Health Asthma Management Platform to better manage chronic respiratory disease.
Patients will have the opportunity to enroll in a new program to determine how Propeller's hi-tech tool can impact adherence rates and patient engagement.
The sensor-laden device with a novel electronic dose counter is currently available for licensing and is expected to enter clinical studies later this year.
GSK will use the sensor in the studies to automatically collect and record data on the inhaler's usage, and wirelessly transmit the data collected.
FDA-approved marketing claims of improved adherence and reduction in exacerbations address key unmet needs in respiratory health.
Safeguard Scientifics led the round, which will be used to accelerate product development, strategic alliances, client services, sales and marketing.